NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE231427 Query DataSets for GSE231427
Status Public on May 15, 2023
Title IgE-binding monocytes upregulate the coagulation cascade in allergic horses
Organism Equus caballus
Experiment type Expression profiling by high throughput sequencing
Summary IgE-binding monocytes are a rare peripheral immune cell type involved in the allergic response through binding of IgE on their surface. IgE-binding monocytes are present in both healthy and allergic individuals. We performed RNA sequencing to ask how the function of IgE-binding monocytes differs in the context of allergy. Using a large animal model of allergy, equine Culicoides hypersensitivity, we compared the transcriptome of IgE-binding monocytes in allergic and non-allergic horses at two seasonal timepoints: (i) when allergic animals were clinical healthy, in the winter “Remission Phase”, and (ii) during chronic disease, in the summer “Clinical Phase”. Most transcriptional differences between allergic and non-allergic horses occurred only during the “Remission Phase”, suggesting principal differences in monocyte function even in the absence of allergen exposure. F13A1, a subunit of fibrinoligase, was significantly upregulated at both timepoints in allergic horses. This suggested a role for increased fibrin deposition in the coagulation cascade to promote allergic inflammation. IgE-binding monocytes also downregulated CCR10 expression in allergic horses during the “Clinical Phase”, suggesting a defect in maintenance of skin homeostasis, which further promotes allergic inflammation. Together, this transcriptional analysis provides valuable clues into the mechanisms used by IgE-binding monocytes in allergic individuals.
 
Overall design Flow cytometry isolated IgE-binding monocytes were purified from equine peripheral blood. Monocytes were purified from allergic (n=7) and healthy (n=5) horses during allergen exposure (Clinical Phase in August-September) and when there was no allergen exposure (Remission Phase in January-February).
 
Contributor(s) Simonin EM, Wagner B
Citation(s) 37193769
Submission date May 01, 2023
Last update date Aug 18, 2023
Contact name Bettina Wagner
E-mail(s) bw73@cornell.edu
Organization name Cornell University
Department Population Medicine and Diagnostic Sciences
Street address 240 Farrier Drive
City Ithaca
State/province NY
ZIP/Postal code 14815
Country USA
 
Platforms (1)
GPL21401 Illumina NextSeq 500 (Equus caballus)
Samples (24)
GSM7277543 IgE+Monocytes, Allergic, Remission Phase EL1
GSM7277544 IgE+Monocytes, Allergic, Remission Phase EL2
GSM7277545 IgE+Monocytes, Allergic, Remission Phase EL3
Relations
BioProject PRJNA965804

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE231427_RAW.tar 2.6 Mb (http)(custom) TAR (of TXT)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap